Plain-English translation of NCT06176885 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment combination for advanced colorectal cancer that has spread to other parts of the body and cannot be removed by surgery. The study combines three types of therapy: chemotherapy drugs (FOLFIRI), a targeted drug called bevacizumab, and an immunotherapy medication called . The goal is to see if this combination approach is effective and safe as a first treatment for patients with a specific type of colorectal cancer.
Most people with advanced colorectal cancer that cannot be surgically removed have limited treatment options. Researchers believe that combining traditional chemotherapy with newer immunotherapy approaches might help more patients respond to treatment and potentially make their tumors shrinkable or removable through surgery.
You likely qualify if…
You likely don't qualify if…
If enrolled, you would receive induction therapy consisting of chemotherapy infusions and bevacizumab, followed by the addition of immunotherapy. The study involves visits to the clinic for treatment administration, blood tests, and imaging scans to monitor how well the treatment is working. You would be one of approximately 36 participants in this trial, and the research team would carefully track both the benefits and any side effects you experience.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China